X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GV-971 (sodium oligomannate), demonstrated significant efficacy in improving cognition with sustained improvement across all observation periods of a 36-week trial. GV-971 was safe and well-tolerated.
Lead Product(s): Sodium Oligomannate
Therapeutic Area: Neurology Product Name: GV-971
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2022
Details:
Green Valley’s treatment, known as GV-971, relies on a type of sugar extracted from brown algae. The drug aims to treat imbalances in the microbiome of the gut, which researchers believe may cause inflammation in the brain and may lead to Alzheimer’s or Parkinson’s disease.
Lead Product(s): Sodium Oligomannate
Therapeutic Area: Neurology Product Name: GV-971
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.
Lead Product(s): Sodium oligomannate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
